Review





Similar Products

bnt162b2 vaccine  (Pfizer Inc)
90
Pfizer Inc bnt162b2 vaccine
Bnt162b2 Vaccine, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bnt162b2 vaccine/product/Pfizer Inc
Average 90 stars, based on 1 article reviews
bnt162b2 vaccine - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
bnt162b2  (Pfizer Inc)
86
Pfizer Inc bnt162b2
Bnt162b2, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bnt162b2/product/Pfizer Inc
Average 86 stars, based on 1 article reviews
bnt162b2 - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
bnt162b2  (Moderna)
86
Moderna bnt162b2
Bnt162b2, supplied by Moderna, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bnt162b2/product/Moderna
Average 86 stars, based on 1 article reviews
bnt162b2 - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
bivalent bnt162b2  (Pfizer Inc)
86
Pfizer Inc bivalent bnt162b2
Longitudinal measurements and kinetics of SARS-CoV-2 anti-spike (S) antibody over a 1-y study period. (a) Level of anti-S antibody between different vaccine groups. Data was analysed using one-way ANOVA with Holm-Sidak’s multiple comparisons test. Bars depict mean and 95% CI. (b) Kinetics of anti-S antibody from D28 post-booster. Data presented are geometric mean concentrations and 95% CI. (c) Summary data. (d) Comparison of anti-S titres at D28, D180 and D360, and D360-to-D28 ratio. One multiple linear regression model was fitted for each time point, adjusting for baseline anti-S titres, age group (<60 y; ≥60 y), the interval between first and second boosters (≤1 y; >1 y), primary vaccination series (mRNA-1273; <t>BNT162b2),</t> first booster (mRNA-1273; BNT162b2), sex and prior SARS-CoV-2 infection. GM: geometric mean; GMR: geometric mean ratio. *** p < .001; **** p < .0001.
Bivalent Bnt162b2, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bivalent bnt162b2/product/Pfizer Inc
Average 86 stars, based on 1 article reviews
bivalent bnt162b2 - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
pfizer bnt162b2  (Pfizer Inc)
86
Pfizer Inc pfizer bnt162b2
Longitudinal measurements and kinetics of SARS-CoV-2 anti-spike (S) antibody over a 1-y study period. (a) Level of anti-S antibody between different vaccine groups. Data was analysed using one-way ANOVA with Holm-Sidak’s multiple comparisons test. Bars depict mean and 95% CI. (b) Kinetics of anti-S antibody from D28 post-booster. Data presented are geometric mean concentrations and 95% CI. (c) Summary data. (d) Comparison of anti-S titres at D28, D180 and D360, and D360-to-D28 ratio. One multiple linear regression model was fitted for each time point, adjusting for baseline anti-S titres, age group (<60 y; ≥60 y), the interval between first and second boosters (≤1 y; >1 y), primary vaccination series (mRNA-1273; <t>BNT162b2),</t> first booster (mRNA-1273; BNT162b2), sex and prior SARS-CoV-2 infection. GM: geometric mean; GMR: geometric mean ratio. *** p < .001; **** p < .0001.
Pfizer Bnt162b2, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pfizer bnt162b2/product/Pfizer Inc
Average 86 stars, based on 1 article reviews
pfizer bnt162b2 - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
ancestral monovalent wt pfizer bnt162b2 vaccine  (Pfizer Inc)
86
Pfizer Inc ancestral monovalent wt pfizer bnt162b2 vaccine
Longitudinal measurements and kinetics of SARS-CoV-2 anti-spike (S) antibody over a 1-y study period. (a) Level of anti-S antibody between different vaccine groups. Data was analysed using one-way ANOVA with Holm-Sidak’s multiple comparisons test. Bars depict mean and 95% CI. (b) Kinetics of anti-S antibody from D28 post-booster. Data presented are geometric mean concentrations and 95% CI. (c) Summary data. (d) Comparison of anti-S titres at D28, D180 and D360, and D360-to-D28 ratio. One multiple linear regression model was fitted for each time point, adjusting for baseline anti-S titres, age group (<60 y; ≥60 y), the interval between first and second boosters (≤1 y; >1 y), primary vaccination series (mRNA-1273; <t>BNT162b2),</t> first booster (mRNA-1273; BNT162b2), sex and prior SARS-CoV-2 infection. GM: geometric mean; GMR: geometric mean ratio. *** p < .001; **** p < .0001.
Ancestral Monovalent Wt Pfizer Bnt162b2 Vaccine, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ancestral monovalent wt pfizer bnt162b2 vaccine/product/Pfizer Inc
Average 86 stars, based on 1 article reviews
ancestral monovalent wt pfizer bnt162b2 vaccine - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier

Image Search Results


Longitudinal measurements and kinetics of SARS-CoV-2 anti-spike (S) antibody over a 1-y study period. (a) Level of anti-S antibody between different vaccine groups. Data was analysed using one-way ANOVA with Holm-Sidak’s multiple comparisons test. Bars depict mean and 95% CI. (b) Kinetics of anti-S antibody from D28 post-booster. Data presented are geometric mean concentrations and 95% CI. (c) Summary data. (d) Comparison of anti-S titres at D28, D180 and D360, and D360-to-D28 ratio. One multiple linear regression model was fitted for each time point, adjusting for baseline anti-S titres, age group (<60 y; ≥60 y), the interval between first and second boosters (≤1 y; >1 y), primary vaccination series (mRNA-1273; BNT162b2), first booster (mRNA-1273; BNT162b2), sex and prior SARS-CoV-2 infection. GM: geometric mean; GMR: geometric mean ratio. *** p < .001; **** p < .0001.

Journal: Human Vaccines & Immunotherapeutics

Article Title: NVX-CoV2372, monovalent mRNA and bivalent mRNA vaccines elicit broadly cross-reactive antibodies against emerging SARS-CoV-2 variants

doi: 10.1080/21645515.2026.2638022

Figure Lengend Snippet: Longitudinal measurements and kinetics of SARS-CoV-2 anti-spike (S) antibody over a 1-y study period. (a) Level of anti-S antibody between different vaccine groups. Data was analysed using one-way ANOVA with Holm-Sidak’s multiple comparisons test. Bars depict mean and 95% CI. (b) Kinetics of anti-S antibody from D28 post-booster. Data presented are geometric mean concentrations and 95% CI. (c) Summary data. (d) Comparison of anti-S titres at D28, D180 and D360, and D360-to-D28 ratio. One multiple linear regression model was fitted for each time point, adjusting for baseline anti-S titres, age group (<60 y; ≥60 y), the interval between first and second boosters (≤1 y; >1 y), primary vaccination series (mRNA-1273; BNT162b2), first booster (mRNA-1273; BNT162b2), sex and prior SARS-CoV-2 infection. GM: geometric mean; GMR: geometric mean ratio. *** p < .001; **** p < .0001.

Article Snippet: In Singapore, the bivalent mRNA-1273 (ancestral/BA.1, Moderna) and bivalent BNT162b2 (ancestral/BA.4/5, Pfizer) vaccines were added to the National Vaccination Programme from October 2022 and were recommended in place of the original monovalent vaccines.

Techniques: Comparison, Infection